Blood Parathyrin and Mineral Metabolism Dynamics
A clinical analyze

LUCRETIU RADU1, MARA CARSOȚE2*, ANCUTA AUGUSTINA GHERGHIȘAN GALATEANU3, SMARANDA ADELINA PREDA1, VERONICA CALBOREAN4, RADU STANESCU1, VICTOR GHEORAMAN5, DANA MARIA ALBULESCU6

1 University of Medicine and Pharmacy, Craiova, Department of Hygiene, CFR Hospital of Craiova, Stărbei-Voda Str., 200374, Craiova, Romania
2 Carol Davila University of Medicine and Pharmacy Department of Endocrinology, C.I.Parhon National Institute of Endocrinology, Aviatorilor Av., 34-38, Bucharest, Romania
3 Ph D Student, University of Medicine and Pharmacy, Tabaci Str, 200642, Craiova, Romania
4 University of Medicine and Pharmacy of Craiova, Cardiology Department, County Hospital Craiova, 2-4 Petru Rares Str., 200349, Craiova, Romania
5 University of Medicine and Pharmacy, Craiova Department of Anatomy, County Hospital Craiova, 2-4 Petru Rares Str., 200349, Craiova, Romania
6 University of Medicine and Pharmacy of Craiova, Psychiatry Department, Neuropsychiatry Hospital of Craiova, 99 Calea București, 200473, Craiova, Romania

Circulating parathyrin (PTH or parthormon) is increased in primary hyperparathyroidism (PHP) in association with high total/ionic calcium (T/I Ca) and others mineral metabolism anomalies. This is a clinical cross-sectional and case-control study analyzing these changes after PHP surgical correction in menopausal women. Baseline parameters were: mean age at diagnosis (59.63±9.6 years), TCa of 10.9±0.7 mg/dL, PTH of 138.02±59.36 pg/mL. Longitudinal data showed: final TCa p<0.00001, ICa p<0.00001, phosphorus p<0.0001, magnesium p=0.9, 24-h urinary calcium p=0.4, 25-hydroxycholecalciferol p=0.01, PTH p<0.00001. High circulating parathyrin values due to PHP normalized after surgery in addition to statistical significant changes of TCa, ICa, P, lumbar Bone Mineral Density provided by Dual-Energy X-Ray Absorptiometry; Mg and 24-h Ca might not be a marker of general mineral metabolism improvement.

Keywords: parathyryn, parathormone, bone, calcium

Parathyrin represents parthormone (PTH) or parathyroid hormone, the product of parathyroid glands [1]. Many diseases of the bone like primary/secondary osteoporosis or osteomalacia induce changes of circulating parathyrin [2-4]. Even metabolic conditions like metabolic syndrome and/or each of its components are linked to anomalies of bone turnover markers (BTM) and bone hormones including 25-hydroxyvitamin D (25OHD) and PTH. [5-8] Moreover, endocrine tumours or dysfunction of different endocrine glands may lead to skeleton anomalies like increase bone resorption or hypovitaminosis D with potential secondary parathyrin raise, for instance, in endogenous or exogenous glucocorticoids excess or in hypogonadism [9-13]. However, the most important change of mineral metabolism regarding parathyrin is expected in primary hyperparathyroidism (PHP) which is a clinical condition caused by a PTH producing tumour, usually of benign type. [2,3] Surgical tumour removal is the best therapy which is typically followed by a normalisation of circulating parathyrin and serum calcium, as well as of serum phosphorus, and bone turnover markers, and a significant improvement of bone mineral density (BMD) [2,3].

Parathyrin is a biochemical product acting on bone metabolism: it activates the renal induction of 1,25-dihydroxycholecalciferol, the active form of vitamin D (also named calcitriol), bone remodelling, and via its mechanisms PTH exerts a negative feedback with serum calcium: high blood calcium inhibits parathyroid cells while low calcemia stimulates it [1-3]. Chemical aspects of PTH include the primary secreted pro-hormone (a polypeptide

![Parathyrin (PTH)](image)

Fig. 1. Parathormone or parthyrin is a molecule of 84 amino acids, the active end is N-terminal and the active part which actually activates the specific receptors is represented by N-end -34 amino acids
of 84 amino acids) and the active hormone (a section of 34 amino acids), responsible for the activation of type 1 and type 2 parathyroid receptors [1-3]. Parathyrin has a molecular mass of 9500 Da. Figure 1 illustrates the chemical aspects of the PTH as molecule into human body [1].

**Experimental part**

The aim of the study

Our purpose is to study the changes of PTH levels and others mineral metabolism elements in patients with primary hyperparathyroidism who suffered the parathyroid tumour removal (PTR).

**Material and method**

The study design includes a cross-sectional descriptive part which represents the baseline data of the patients and a longitudinal analyze in order to point out the changes between baseline (pre-operative) and post-surgery mineral parameters dynamics. The longitudinal study is case-control because each subject becomes his own control. The data were provided by two centres of endocrinology and the patients agreed for anonymously use of their medical data. Data collection (Excel) and statistical analysis (SPSS) included descriptive parameters like mean, standard deviation (SD), median, and functions as student t test and linear regression. Statistical significance was for p<0.05.

**Subjects**

The inclusion criteria were:
1. Female subjects
2. Menopausal status
3. At least one year of secondary amenorrhea
4. Informed written consent
5. Confirmation of PHP by each patient’s current physician
6. Available data of mineral metabolism pre- and post-operatory
7. Lumbar DXA scan at baseline
The exclusion criteria were:
1. Non-PTH-related causes of high serum calcium
2. Active cancers
3. Bone primary or secondary neoplasia
4. Others (non-PHP) bone metabolic conditions as Paget’s disease, multiple myeloma
5. Prior or current exposure to specific drugs for osteoporosis like bisphosphonates, denosumab, teriparatide
6. Lack of confirmation of a benign parathyroid tumour after PTR based on pathological report
7. Chronic renal failure
8. Prior or current HRT (Hormone Replacement Therapy) for menopause
9. Persistent or recurrent PHP after a previous attempt of PTR.

**Evaluation**

First (baseline) assessment is represented by the first diagnosis of PHP. The longitudinal analyze (the second assessment) was performed after PTR at one to 6 months, and it included the previously mentioned parameters 1 to 9. The same analyzer and method was used for each parameter before and after PTR (fig. 2).

The baseline parameters included:
1. Patient’s age at diagnosis of PHP
2. The calculation of years since menopause (based on last menstruation)
3. Calculated BMI (Body Mass Index) using weight, and height (table 1).
4. Biochemical data: total serum calcium (TCa), ionic serum calcium (ICa), total proteins, serum phosphorus and magnesium, 24 h urinary calcium (24-h Ca).
5. Blood BTM meaning bone formation markers (alkaline phosphatase, and osteocalcin), respective bone resorption marker (CrossLaps).
6. Circulating hormones of bone metabolism: 25OHD and PTH.

The methods of detection for each parameter are introduced in table 2. The normal values of measured/calculated parameters are introduced in table 3.

7. Lumbar central DXA (Dual-Energy X-Ray Absorptiometry) based on a General Electric Lunar Prodigy device. DXA provided lumbar BMD and device-derived T-score and Z-score.

**Results and discussions**

22 females of mean 59.63 years were evaluated at baseline and after PTR. They were all confirmed with PTH. The period of time between first diagnosis and post-operative assessment was 6-12 months. The baseline demographic parameters of menopausal population are included in table 4. The bone parameters analyzed in the study were included in table 5. Average values of TCa, ICa, PTH were outside the normal ranges, mean serum phosphorus had a low-normal value while magnesium was within normal limits, as well as BTM, and 24-h Ca (table 5). The values of PTH were all abnormally increased as part of primary diagnosis (table 5). Figure 3 introduced the circulating values of parathyrin at the moment of PHP confirmation. 25OHD showed prevalent low values (table 5). Lumbar BMD analyze provided a mean value of osteo-

**Table 1**

**FORMULAS OF CALCULATION FOR BODY MASS INDEX, TOTAL CALCIUM AND IONIC CALCIUM**

<table>
<thead>
<tr>
<th>Formula</th>
<th>Abbreviation</th>
<th>Calculation</th>
<th>Units</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body Mass Index</td>
<td>BMI</td>
<td>weight (kg) / (height m)^2 (sqm)</td>
<td>kg/sqm</td>
</tr>
<tr>
<td>Corrected serum total</td>
<td>TCa</td>
<td>Measured TCa (mg/dL) + 0.8(4-measured serum albumin (g/dL))</td>
<td>mg/dL</td>
</tr>
<tr>
<td>Calcium</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ionic calcium</td>
<td>ICa</td>
<td>[6XTCa(mg/dL) – measured total proteins (g/dL)] ÷ 3][total proteins(g/dL) ÷ 6]</td>
<td>mg/dL</td>
</tr>
</tbody>
</table>

---

**Fig. 2. Timing of assessment according to longitudinal clinical analyze**

---

**Table 2**

---

**Table 3**

---

**Table 4**

---

**Table 5**

---
Table 2
METHOD OF ASSAY FOR BONE BIOCHEMISTRY, BONE TURNOVER MARKERS AND BONE HORMONES

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Method of detection</th>
</tr>
</thead>
<tbody>
<tr>
<td>serum calcium</td>
<td>colorimetric</td>
</tr>
<tr>
<td>total proteins</td>
<td>colorimetric</td>
</tr>
<tr>
<td>serum phosphorus</td>
<td>colorimetric</td>
</tr>
<tr>
<td>magnesium</td>
<td>colorimetric</td>
</tr>
<tr>
<td>24-hours urinary calcium</td>
<td>spectrophotometry</td>
</tr>
<tr>
<td>alkaline phosphatase</td>
<td>colorimetric (VITROS)</td>
</tr>
<tr>
<td>osteocalcin</td>
<td>electro-chemiluminescence</td>
</tr>
<tr>
<td>CrossLaps</td>
<td>electro-chemiluminescence</td>
</tr>
<tr>
<td>25-hydroxyvitamin D or (25(OH)D3)</td>
<td>chemiluminescence</td>
</tr>
</tbody>
</table>

Table 3
NORMAL VALUES OF MEASURED/CALCULATED PARAMETERS

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Normal value</th>
</tr>
</thead>
<tbody>
<tr>
<td>total serum calcium</td>
<td>8.5 - 10.2 mg/dL</td>
</tr>
<tr>
<td>ionic serum calcium</td>
<td>3.9 - 4.9 mg/dL</td>
</tr>
<tr>
<td>total proteins*</td>
<td>6.5 - 8.7 mg/dL</td>
</tr>
<tr>
<td>serum phosphorus</td>
<td>2.5 - 4.5 mg/dL</td>
</tr>
<tr>
<td>magnesium</td>
<td>1.6 - 2.55 mg/dL</td>
</tr>
<tr>
<td>24-hours urinary calcium</td>
<td>0.1 - 0.4 g/24-hours</td>
</tr>
<tr>
<td>alkaline phosphatase</td>
<td>38 - 105 U/L</td>
</tr>
<tr>
<td>osteocalcin</td>
<td>15 - 45 ng/mL</td>
</tr>
<tr>
<td>CrossLaps</td>
<td>0.33 - 0.72 mg/mL</td>
</tr>
<tr>
<td>25-hydroxyvitamin D (25(OH)D3)</td>
<td>30 - 100 ng/mL</td>
</tr>
</tbody>
</table>

*not a bone parameter but a necessary tool to calculate corrected total calcium and ionic calcium

Table 4
THE BASELINE DEMOGRAPHIC PARAMETERS OF STUDIED POPULATION (N=22)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at diagnosis</td>
<td>59.63 (SD 9.09)</td>
</tr>
<tr>
<td>Age at menopause</td>
<td>51 (SD 11)</td>
</tr>
<tr>
<td>Years since menopause</td>
<td>8.04 (SD 3.43)</td>
</tr>
<tr>
<td>BMI</td>
<td>27.69 (SD 2.72)</td>
</tr>
</tbody>
</table>

Where: BMI = Body Mass Index (kg/sqm); age at diagnosis, age at menopause are expressed in years

Table 5
THE BONE PARAMETERS ANALYSED IN MENOPAUSAL POPULATION CONFIRMED WITH PHP

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Tc</th>
<th>Tc</th>
<th>TP</th>
<th>P</th>
<th>Mg</th>
<th>24-h Ca</th>
<th>AP</th>
<th>CL</th>
<th>OC</th>
<th>25OH D</th>
<th>PTH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean</td>
<td>10.904</td>
<td>4.6918</td>
<td>7.3942</td>
<td>2.64904</td>
<td>2.0831</td>
<td>0.2411</td>
<td>11</td>
<td>85.06</td>
<td>0.4346</td>
<td>28.413</td>
<td>15.920</td>
</tr>
<tr>
<td>SD</td>
<td>0.7563</td>
<td>0.4801</td>
<td>0.4801</td>
<td>0.49384</td>
<td>0.1919</td>
<td>0.0056</td>
<td>78</td>
<td>24.237</td>
<td>0.2406</td>
<td>10.993</td>
<td>8.6217</td>
</tr>
<tr>
<td>Median</td>
<td>10.8</td>
<td>4.7</td>
<td>7.28</td>
<td>2</td>
<td>0.22</td>
<td>0.455</td>
<td>22.19</td>
<td>14.495</td>
<td>111.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Min</td>
<td>9.02</td>
<td>3.6</td>
<td>5.52</td>
<td>0.41</td>
<td>1.41</td>
<td>0.14</td>
<td>0.05</td>
<td>0.05</td>
<td>0.14</td>
<td>0.05</td>
<td>14.15</td>
</tr>
<tr>
<td>Max</td>
<td>12.6</td>
<td>3.75</td>
<td>8.2</td>
<td>3.33</td>
<td>2.5</td>
<td>0.38</td>
<td>0.75</td>
<td>46.72</td>
<td>30.31</td>
<td>233.2</td>
<td></td>
</tr>
</tbody>
</table>

Where: Tc = total calcium (mg/dL), Tc = ionic calcium (mg/dL), TP = total protein (g/dL), P = phosphorus (mg/dL), Mg = magnesium (mg/dL), 24-h Ca = 24-h urinary calcium (g/24-h), AP = alkaline phosphatase (U/L), CL = CrossLaps (ng/mL), OC = osteocalcin (ng/mL), 25OH D = 25-hydroxyvitamin D (ng/mL), PTH = parathormone (pg/mL)

Fig. 3. The values of circulating parathyrin in each of the menopausal women confirmed with PHP
penia according to T-score (table 6). Longitudinal data showed that bone parameters normalized according to mean values (table 7). None of the patients had persistent PHP during the mentioned period of time (table 7). The values of 25OHD improved after PTR (table 7). DXA results after PTR showed a mean T-score of -1.2±0.09 SD with a median of -1.267 SD (ranges between -1.3 and -1.2 SD). The baseline correlation between TCa/ICa and PTH did not reach the statistical significance. Student t test between baseline and follow-up bone values showed the following results for:

1. TCa: p<0.00001
2. ICa:  p<0.00001
3. P: p<0.0001
4. Mg: p=0.9
5. 24-h Ca: p=0.4
6. AP: p=0.09
7. CL: p=0.03
8. OC: p=0.09
9. 25OHD: p=0.01
10. PTH: p<0.00001
11. BMD: p<0.00001

The strengths of the study are the fact that is based on real life medicine which provided biochemical and endocrine data; the longitudinal observations are introduced using a case-control study, each subject represents his own control. Also, the numerous statistical significant results confirmed the literature regarding the mineral metabolism improvement once the circulating parathyryn is corrected after PTR. We achieved statistical significant data for TCa, ICa, PTH, P, lumbar BMD-DXA; Mg and 24-h Ca might not be a marker of general mineral metabolism improvement.

The weak aspects of the study are the sample size of the cohort; the relative low period of time for surveillance; the changes of 25OHD are also due to the iatrogenic intervention once the diagnosis of vitamin D deficit was established by the same time with PHP confirmation; a very small number of patients had a high value of total calcium after PTR but with normal PTH, probably due to the introduction of calcium supplements immediately after PTR; also one patient had the maximum value of PTH after PTR of 127.1 pg/mL which was considered a component of secondary hyperparathyroidism due to low 25OHD levels and after vitamin D supplementation parathyryn normalized (the case was not considered a persistent PHP which are not included in the current study).

Generally the results for 25OHD showed hypo-vitaminosis D which partially corrected after PTR.

Conclusions
High circulating parathyryn values due to PHP normalized after PTR in addition to statistical significant changes of TCa, ICa, P lumbar BMD-DXA; Mg and 24-h Ca might not be a marker of general mineral metabolism improvement.

Abbreviations
AP = Alkaline Phosphatase
BMI = Body Mass Index
BTM = Bone Turnover Markers
BMD = Bone Mineral Density
CL = CrossLaps
24-h Ca = 24-hours urinary calcium
25OHD = 25-hydroxyvitamin D
HRT = Hormone Replacement Therapy
ICa = ionic serum calcium
PTH = parathormone, parathyryn
P = Phosphorus
S.D = standard deviation
TCa = total calcium (mg/dL)
TP = total protein (g/dL)
Mg = magnesium
OC = osteocalcin
PHP = primary hyperparathyroidism
PTR = parathyroid tumour removal
P = Phosphorus
SD = standard deviation
TCa = total serum calcium
TP = total proteins

References
1. https://en.wikipedia.org/wiki/Parathyroid_hormone
6. POIANA, C., RADOI, V., CARSOTE, M., BILEZEKIAN, J., Bone Research, 1, nr. 3, 2013, p. 260
10. PREDA S.A., BISTRICEANU M., BISTRICEANU I., ALBULESCU D.M., CONSTANTIN C., MARIOARA O.M., TURCULEANU A., COVEI A., CAMEN A., Osteoporosis International with other metabolic bone diseases WCO-IOF-ESCEO, World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, 14-17 April 2016, Malaga, Spain Malaga, volume 27 supplement 1, april 2016 p 293
11. BONDARI S, A. COVEI, A. TURCULEANU, D. M. ALBULESCU, O. M. MARIOARA, A. CAMEN, Osteoporosis International with other metabolic bone diseases world congress of osteoporosis, osteoarthritis and musculoskeletal diseases 26/29 march, 2015 Milan, Italy, volume 26 supplement 1, March 2015, p. 216
12. BUGALA, S.A, PAVEL, OR, PAVEL, LP, VASILE, IS, STEFAN, E. COVEI, A, CAMEN, A, ENESCU, A, ENESCU, AS, IONOVI, N. ALBULESCU, DM, Osteoporosis International with other metabolic bone diseases WCO-IOF-ESCEO, World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, 29, nr. SUPPLEMENT 1, 2018, p. 456

Manuscript received: 11.02.2018